The proteins of the BCL-2 family are key regulators of mitochondrial apoptosis, acting as
either promoters or inhibitors of cell death. The functional interplay and balance between the …

A major obstacle in the treatment of acute myeloid leukemia (AML) is refractory disease or
relapse after achieving remission. The latter arises from a few therapy-resistant cells within …

The BCL-2 family protein BAX is a major regulator of physiological and pathological cell
death. BAX predominantly resides in the cytosol in a quiescent state and upon stress, it …

Adoptive cell therapies engineered to express chimeric antigen receptors (CARs) or
transgenic T cell receptors (TCRs) to recognize and eliminate cancer cells have emerged as …

RNA splicing factors are recurrently mutated in clonal blood disorders, but the impact of
dysregulated splicing in hematopoiesis remains unclear. To overcome technical limitations …

BH3-mimetic drugs are an anti-cancer therapy that can induce apoptosis in malignant cells
by directly binding and inhibiting pro-survival proteins of the BCL-2 family. The BH3-mimetic …

Deregulated apoptosis signaling is characteristic for many cancers and contributes to
leukemogenesis and treatment failure in B-cell precursor acute lymphoblastic leukemia …

TP53-mutant acute myeloid leukemia (AML) respond poorly to currently available
treatments, including venetoclax-based drug combinations and pose a major therapeutic …

Venetoclax is a strongly effective B-cell lymphoma-2 inhibitor (BCL-2) with an ability to
selectively restore the apoptotic potential of cancerous cells. It has been proven that in …

The combination of venetoclax (VEN) and azacitidine (AZA) has become the standard of
care for acute myeloid leukemia (AML) patients who are≥ 75 years or unfit for intensive …